| 发明名称 | Treatment of fibrosis using FXR ligands | ||
| 摘要 | The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions. | ||
| 申请公布号 | US9498484(B2) | 申请公布日期 | 2016.11.22 |
| 申请号 | US200511081002 | 申请日期 | 2005.03.14 |
| 申请人 | Intercept Pharmaceuticals, Inc. | 发明人 | Fiorucci Stefano;Pellicciari Roberto;Pruzanski Mark |
| 分类号 | A61K31/56 | 主分类号 | A61K31/56 |
| 代理机构 | Cooley LLP | 代理人 | Cooley LLP ;Elrifi Ivor R.;Erlacher Heidi A. |
| 主权项 | 1. A method of treating liver fibrosis in a human not suffering from a cholestatic condition, comprising the steps of selecting a human who is not suffering from a cholestatic condition and administering to the human 6-ethyl-chenodeoxycholic acid at a daily dose of 5-500 mg orally. | ||
| 地址 | New York NY US | ||